Reuters logo
BRIEF-Trovagene's PCM-075 demonstrates Synergy with Zytiga
2017年10月18日 / 下午1点00分 / 1 个月前

BRIEF-Trovagene's PCM-075 demonstrates Synergy with Zytiga

Oct 18 (Reuters) - Johnson & Johnson

* Trovagene Inc - ‍announced positive data from preclinical research demonstrating synergy of PCM-075 in combination with abiraterone (Zytiga)​

* Trovagene- data shows ‍PCM-075 enhances activity of abiraterone in mCRPC tumors cells & may represent treatment option to extend benefit of anti-androgen therapy​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below